Pharmacodynamics and safety in relation to dose and response of plant flavonoids in treatment of cancers.

IF 4.6 2区医学 Q2 IMMUNOLOGY Inflammopharmacology Pub Date : 2024-11-24 DOI:10.1007/s10787-024-01581-1

Cijo George Vazhappilly, Seba Alsawaf, Shimy Mathew, Noora Ali Nasar, Maheen Imtiaz Hussain, Noor Mustapha Cherkaoui, Mohammed Ayyub, Serin Yaser Alsaid, Joshua George Thomas, Asha Caroline Cyril, Wafaa S Ramadan, Ayshwarya Lakshmi Chelakkot

{"title":"Pharmacodynamics and safety in relation to dose and response of plant flavonoids in treatment of cancers.","authors":"Cijo George Vazhappilly, Seba Alsawaf, Shimy Mathew, Noora Ali Nasar, Maheen Imtiaz Hussain, Noor Mustapha Cherkaoui, Mohammed Ayyub, Serin Yaser Alsaid, Joshua George Thomas, Asha Caroline Cyril, Wafaa S Ramadan, Ayshwarya Lakshmi Chelakkot","doi":"10.1007/s10787-024-01581-1","DOIUrl":null,"url":null,"abstract":"<p><p>Despite the recent advancements in developing bioactive nutraceuticals as anticancer modalities, their pharmacodynamics, safety profiles, and tolerability remain elusive, limiting their success in clinical trials. The failure of anticancer drugs in clinical trials can be attributed to the changes in drug clearance, absorption, and cellular responses, which alter the dose-response efficacy, causing adverse health effects. Flavonoids demonstrate a biphasic dose-response phenomenon exerting a stimulatory or inhibitory effect and often follow a U-shaped curve in different preclinical cancer models. A double-edged sword, bioflavonoids' antioxidant or prooxidant properties contribute to their hormetic behavior and facilitate redox homeostasis by regulating the levels of reactive oxygen species (ROS) in cells. Emerging reports suggest a need to discuss the pharmacodynamic broad-spectrum of plant flavonoids to improve their therapeutic efficacy, primarily to determine the ideal dose for treating cancer. This review discusses the dose-response effects of a few common plant flavonoids against some types of cancers and assesses their safety and tolerability when administered to patients. Moreover, we have emphasized the role of dietary-rich plant flavonoids as nutraceuticals in cancer treatment and prevention.</p>","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":""},"PeriodicalIF":4.6000,"publicationDate":"2024-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Inflammopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10787-024-01581-1","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Despite the recent advancements in developing bioactive nutraceuticals as anticancer modalities, their pharmacodynamics, safety profiles, and tolerability remain elusive, limiting their success in clinical trials. The failure of anticancer drugs in clinical trials can be attributed to the changes in drug clearance, absorption, and cellular responses, which alter the dose-response efficacy, causing adverse health effects. Flavonoids demonstrate a biphasic dose-response phenomenon exerting a stimulatory or inhibitory effect and often follow a U-shaped curve in different preclinical cancer models. A double-edged sword, bioflavonoids' antioxidant or prooxidant properties contribute to their hormetic behavior and facilitate redox homeostasis by regulating the levels of reactive oxygen species (ROS) in cells. Emerging reports suggest a need to discuss the pharmacodynamic broad-spectrum of plant flavonoids to improve their therapeutic efficacy, primarily to determine the ideal dose for treating cancer. This review discusses the dose-response effects of a few common plant flavonoids against some types of cancers and assesses their safety and tolerability when administered to patients. Moreover, we have emphasized the role of dietary-rich plant flavonoids as nutraceuticals in cancer treatment and prevention.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

植物黄酮治疗癌症的药效学和安全性与剂量和反应的关系。

尽管最近在开发生物活性营养保健品作为抗癌方式方面取得了进展，但其药效学、安全性和耐受性仍然难以捉摸，限制了其在临床试验中的成功。抗癌药物在临床试验中的失败可归因于药物清除、吸收和细胞反应的变化，这些变化改变了剂量-反应疗效，对健康造成不良影响。黄酮类化合物在不同的临床前癌症模型中表现出双相剂量-反应现象，产生刺激或抑制作用，通常呈 U 型曲线。作为一把双刃剑，生物类黄酮的抗氧化或促氧化特性有助于其激素行为，并通过调节细胞中活性氧（ROS）的水平促进氧化还原平衡。新近的报告表明，有必要讨论植物黄酮的药效学广谱性，以提高其疗效，主要是确定治疗癌症的理想剂量。本综述讨论了几种常见植物黄酮类化合物对某些类型癌症的剂量反应效应，并评估了给患者用药时的安全性和耐受性。此外，我们还强调了膳食中富含的植物类黄酮作为营养保健品在癌症治疗和预防中的作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Inflammopharmacology IMMUNOLOGYTOXICOLOGY-TOXICOLOGY

CiteScore

8.00

自引率

3.40%

发文量

200

期刊介绍： Inflammopharmacology is the official publication of the Gastrointestinal Section of the International Union of Basic and Clinical Pharmacology (IUPHAR) and the Hungarian Experimental and Clinical Pharmacology Society (HECPS). Inflammopharmacology publishes papers on all aspects of inflammation and its pharmacological control emphasizing comparisons of (a) different inflammatory states, and (b) the actions, therapeutic efficacy and safety of drugs employed in the treatment of inflammatory conditions. The comparative aspects of the types of inflammatory conditions include gastrointestinal disease (e.g. ulcerative colitis, Crohn''s disease), parasitic diseases, toxicological manifestations of the effects of drugs and environmental agents, arthritic conditions, and inflammatory effects of injury or aging on skeletal muscle. The journal has seven main interest areas: -Drug-Disease Interactions - Conditional Pharmacology - i.e. where the condition (disease or stress state) influences the therapeutic response and side (adverse) effects from anti-inflammatory drugs. Mechanisms of drug-disease and drug disease interactions and the role of different stress states -Rheumatology - particular emphasis on methods of measurement of clinical response effects of new agents, adverse effects from anti-rheumatic drugs -Gastroenterology - with particular emphasis on animal and human models, mechanisms of mucosal inflammation and ulceration and effects of novel and established anti-ulcer, anti-inflammatory agents, or antiparasitic agents -Neuro-Inflammation and Pain - model systems, pharmacology of new analgesic agents and mechanisms of neuro-inflammation and pain -Novel drugs, natural products and nutraceuticals - and their effects on inflammatory processes, especially where there are indications of novel modes action compared with conventional drugs e.g. NSAIDs -Muscle-immune interactions during inflammation [...]